Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts

American Journal of Physiology - Cell Physiology

Volumn 310, Issue 4, 2016, Pages C270-C283

  Du, Jianfeng ^a   Zhang, Ling ^b   Wang, Zhengke ^a   Yano, Naohiro ^b   Zhao, Yu Tina ^a   Wei, Lei ^b   Dubielecka Szczerba, Patrycja ^b   Liu, Paul Y ^b   Zhuang, Shougang ^b   Qin, Gangjian ^c   Zhao, Ting C ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Akt 1; Function; Glucagon like peptide 1 receptor; MAPK kinase 3; Myocardial infarction

Indexed keywords

AKT 1 PROTEIN; CASPASE 3; COLLAGEN; EXENDIN 4; FIBRONECTIN; HYDROXYPROLINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; AKT1 PROTEIN, MOUSE; APOPTOSIS REGULATORY PROTEIN; CARDIOTONIC AGENT; MAP2K3 PROTEIN, MOUSE; PEPTIDE; VENOM;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CARDIAC INTERSTITIAL FIBROSIS; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FIBROSING ALVEOLITIS; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCAR FORMATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; THORACOTOMY; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CARDIOMEGALY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; FIBROSIS; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; KNOCKOUT MOUSE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; TIME FACTOR;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARDIOMEGALY; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FIBROSIS; MAP KINASE KINASE 3; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STROKE VOLUME; TIME FACTORS; VENOMS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84958559505     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00194.2015     Document Type: Article

References (44)

1. Angeli FS, Shannon RP. Incretin-based therapies: can we achieve glycemic control and cardioprotection? J Endocrinol 221: T17-T30, 2014.
2. Araki S, Izumiya Y, Hanatani S, Rokutanda T, Usuku H, Akasaki Y, Takeo T, Nakagata N, Walsh K, Ogawa H. Akt-1-mediated skeletal muscle growth attenuates cardiac dysfunction and remodeling after experimental myocardial infarction. Circ Heart Fail 5: 116-125, 2012.
3. Aronis KN, Chamberland JP, Mantzoros CS. GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism 62: 1279-1286, 2013.
4. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor- dependent and -independent pathways. Circulation 117: 2340-2350, 2008.
5. Barakat GM, Nuwayri-Salti N, Kadi LN, Bitar KM, Al-Jaroudi WA, Bikhazi AB. Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts. Gen Physiol Biophys 30: 34-44, 2011.
6. Barragán JM, Rodríguez RE, Eng J, Blázquez E. Interactions of exendin-(9 -39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 67: 63-68, 1996.
7. Bellahcene M, Jacquet S, Cao XB, Tanno M, Haworth RS, Layland J, Kabir AM, Gaestel M, Davis RJ, Flavell RA, Shah AM, Avkiran M, Marber MS. Activation of p38 mitogen-activated protein kinase contributes to the early cardiodepressant action of tumor necrosis factor. J Am Coll Cardiol 48: 545-555, 2006.
8. Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen YT, Shannon RP. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 3: 512-521, 2010.
9. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemiareperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 21: 253-256, 2007.
10. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagonlike peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151, 2005.
11. dos Santos L, Salles TA, Arruda-Junior DF, Campos LC, Pereira AC, Barreto AL, Antonio EL, Mansur AJ, Tucci PJ, Krieger JE, Girardi AC. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail 6: 1029-1038, 2013.
12. Drucker DJ. Biological actions and therapeutic potential of the glucagonlike peptides. Gastroenterology 122: 531-544, 2002.
13. González N, Acitores A, Sancho V, Valverde I, Villanueva-Peñacarrillo ML. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 126: 203-211, 2005.
14. Heo KS, Fujiwara K, Abe J. Glucagon-like peptide-1 and its cardiovascular effects. Curr Atheroscler Rep 14: 422-428, 2012.
15. Katare R, Riu F, Rowlinson J, Lewis A, Holden R, Meloni M, Reni C, Wallrapp C, Emanueli C, Madeddu P. Perivascular delivery of encapsulated mesenchymal stem cells improves postischemic angiogenesis via paracrine activation of VEGF-A. Arterioscler Thromb Vasc Biol 33: 1872-1880, 2013.
16. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88: 3082-3089, 2003.
17. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagonlike peptide-1 receptor signaling modulates cell apoptosis. J Biol Chem 278: 471-478, 2003.
18. Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, Parkes DG. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 9: 76, 2010.
19. Martindale JJ, Wall JA, Martinez-Longoria DM, Aryal P, Rockman HA, Guo Y, Bolli R, Glembotski CC. Overexpression of mitogenactivated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo. J Biol Chem 280: 669-676, 2005.
20. Miao W, Luo Z, Kitsis RN, Walsh K. Intracoronary, adenovirusmediated Akt gene transfer in heart limits infarct size following ischemiareperfusion injury in vivo. J Mol Cell Cardiol 32: 2397-402, 2000.
21. Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, Levine MA, Schwindinger W, Bernier M. Pancreatic glucagon- like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140: 1132-1140, 1999.
22. Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 4: 401-405, 2003.
23. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. GLP-1 increased myocardial glucose uptake and improved LV performance in conscious dogs with pacing induced dilated cardiomyopathy. Circulation 110: 955-961, 2004.
24. Nikolaidis L, Elahi D, Shen Y, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-H2408, 2005.
25. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962-965, 2004.
26. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50: 583-589, 2001.
27. Ravassa S, Zudaire A, Díez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res 94: 316-323, 2012.
28. Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 98: 408-413, 2012.
29. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 29: 225-229, 1996.
30. Richter G, Feddersen O, Wagner U, Barth P, Goke R, Goke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol Lung Cell Mol Physiol 265: L374-L381, 1993.
31. Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, Cheng XW, Okumura T, Hirashiki A, Nagata K, Murohara T. Dipeptidyl peptidase- 4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis- dependent and -independent actions. Circulation 126: 1838-1851, 2012.
32. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115: 2108-2118, 2005.
33. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100: 824-829, 2007.
34. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694-699, 2006.
35. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501-510, 2009.
36. Vyas AK, Yang KC, Woo D, Tzekov A, Kovacs A, Jay PY, Hruz PW. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 6: e17178, 2011.
37. Wright EJ, Farrell KA, Malik N, Kassem M, Lewis AL, Wallrapp C, Holt CM. Encapsulated glucagon-like peptide-1-producing mesenchymal stem cells have a beneficial effect on failing pig hearts. Stem Cells Transl Med 1: 759-769, 2012.
38. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagonlike peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110: 43-52, 2002.
39. Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post myocardial infarction heart failure. Cardiovasc Diabetol 10: 85, 2011.
40. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48: 1026-1034, 1999.
41. Zhao TC, Du J, Zhuang S, Liu P, Zhang LX. HDAC inhibition elicits myocardial protective effect through modulation of MKK3/Akt-1. PLoS One 8: e65474, 2013.
42. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317: 1106-1113, 2006.
43. Zhao TC, Taher MM, Valerie KC, Kukreja RC. p38 Triggers late preconditioning elicited by anisomycin in heart: involvement of NFkappaB and iNOS. Circ Res 89: 915-922, 2001.
44. Zhang L, Chen B, Zhao Y, Dubielecka PM, Wei L, Qin GJ, Chin YE, Wang Y, Zhao TC. Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts. J Biol Chem 287: 39338- 39348, 2012.